# A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Source: https://onco.cc/trials/nct07286331/  
OnCo record `nct07286331` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Doxorubicin in endometrial cancer, run by GlaxoSmithKline, now recruiting.

## Summary

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) is a phase 3 interventional study registered as NCT07286331 by GlaxoSmithKline, with 600 participants planned, started 2026-06-04 and due to reach its primary completion in 2028-02-29. Interventions recorded: Mocertatug rezetecan, Paclitaxel and Doxorubicin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07286331
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy
- Sponsor: GlaxoSmithKline
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT07286331: https://clinicaltrials.gov/study/NCT07286331

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07286331.json